Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T19:14:01.643Z.
Calculation as of: 2026-10-06T19:14:01.643Z.
Quote observation: 2026-10-06T19:10:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cf9736c803d76d66c79e1885a68840785ad6b55ce886a17ac328e1a4bc30d25a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$2.07B
PS Ratio
18463.71
TTM Avg
5525.95
3Y Avg
2026.46
5Y Avg
1527.87
Market Cap
$2.06B
PS Ratio
28.89
TTM Avg
579.78
3Y Avg
2500.10
5Y Avg
1649.97
Market Cap
$2.12B
PS Ratio
N/A
TTM Avg
42.14
3Y Avg
28.96
5Y Avg
28.96
Market Cap
$2.04B
PS Ratio
2.17
TTM Avg
2.54
3Y Avg
3.32
5Y Avg
6.85
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | $2.08B | N/A | N/A | N/A | N/A |
| Alvotech (ALVO)vs › | $2.07B | 4.21 | 2.67 | 6.76 | 13.27 |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | 18463.71 | 5525.95 | 2026.46 | 1527.87 |
| Vericel Corporation (VCEL)vs › | $2.06B | 6.72 | 7.05 | 9.15 | 9.30 |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | 28.89 | 579.78 | 2500.10 | 1649.97 |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 1.43 | 1.42 | 1.59 | 1.61 |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.12B | N/A | 42.14 | 28.96 | 28.96 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.04B | 2.17 | 2.54 | 3.32 | 6.85 |
| UroGen Pharma Ltd. (URGN)vs › | $2.03B | 10.78 | 11.02 | 7.80 | 6.47 |
| Progyny, Inc. (PGNY)vs › | $2.03B | 1.55 | 1.62 | 2.06 | 3.85 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-10 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
